{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:30:22Z","timestamp":1779237022687,"version":"3.51.4"},"reference-count":31,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"DOI":"10.1210\/jc.2017-01606","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T18:05:44Z","timestamp":1505757944000},"page":"3933-3936","source":"Crossref","is-referenced-by-count":46,"title":["Calcimimetic Use in Familial Hypocalciuric Hypercalcemia\u2014A Perspective in Endocrinology"],"prefix":"10.1210","volume":"102","author":[{"given":"Stephen J","family":"Marx","sequence":"first","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"2019041118054632000_B1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/med\/9780199235292.003.0429","volume-title":"Oxford Textbook of Endocrinology and Diabetes","author":"Brown","year":"2011","edition":"2nd ed."},{"key":"2019041118054632000_B2","first-page":"553","volume-title":"Familial hyperparathyroidism (Including MEN, FHH, and HPT-JT). Primer on the Metabolic Bone Diseases and Mineral Metabolism","author":"Arnold","year":"2013","edition":"8th ed."},{"issue":"6","key":"2019041118054632000_B3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00005792-198111000-00002","article-title":"The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds","volume":"60","author":"Marx","year":"1981","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2019041118054632000_B4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-102-4-511","article-title":"Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families","volume":"102","author":"Law","year":"1985","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019041118054632000_B5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jbspin.2009.02.001","article-title":"Familial hypocalciuric hypercalcemia revealed by chondrocalcinosis","volume":"76","author":"Volpe","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"6269","key":"2019041118054632000_B6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bmj.282.6269.1023","article-title":"Familial hypocalciuric hypercalcaemia and acute pancreatitis","volume":"282","author":"Davies","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2019041118054632000_B7","first-page":"L29","article-title":"Letter to the editor: distinguishing typical primary hyperparathyroidism from familial hypocalciuric hypercalcemia by using an index of urinary calcium","volume-title":"J Clin Endocrinol Metab","author":"Marx","year":"2015"},{"issue":"6455","key":"2019041118054632000_B8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"issue":"11","key":"2019041118054632000_B9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1681\/ASN.2012030323","article-title":"Deficiency of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent hypocalciuria","volume":"23","author":"Toka","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2019041118054632000_B10","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/JME-16-0124","article-title":"Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis","volume":"57","author":"Hannan","year":"2016","journal-title":"J Mol Endocrinol"},{"issue":"5","key":"2019041118054632000_B11","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1210\/jc.2015-3442","article-title":"Familial hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism: similarities and differences","volume":"101","author":"Vargas-Poussou","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041118054632000_B12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/EJE-16-0223","article-title":"Heterozygous inactivating CaSR mutations causing neonatal hyperparathyroidism: function, inheritance and phenotype","volume":"175","author":"Glaudo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041118054632000_B13","doi-asserted-by":"crossref","first-page":"R189","DOI":"10.1530\/EJE-15-1028","article-title":"Genetics in endocrinology: gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts","volume":"174","author":"Mayr","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2019041118054632000_B14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1590\/S0004-27302006000400008","article-title":"The calcium-sensing receptor and related diseases","volume":"50","author":"D\u2019Souza-Li","year":"2006","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2019041118054632000_B15","unstructured":"F.H.H. Familial hypocalciuric hypercalcemia. Available at: http:\/\/www.parathyroid.com\/FHH.htm. Accessed 2 October 2017."},{"key":"2019041118054632000_B16","unstructured":"National Institutes of Health Genetics and Rare Disease Information Center. Familial hypocalciuric hypercalcemia. Available at: https:\/\/rarediseases.info.nih.gov\/diseases\/10828\/familial-hypocalciuric-hypercalcemia.  Updated September 23, 2011. Accessed 19 September 2017."},{"key":"2019041118054632000_B17","unstructured":"Orphanet. Familial hypocalciuric hypercalcemia. Available at: http:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=GB&Expert=405. Updated May 2014. Accessed 19 September 2017."},{"issue":"4","key":"2019041118054632000_B18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","article-title":"Calcimimetic and calcilytic drugs: feats, flops, and futures","volume":"98","author":"Nemeth","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"2019041118054632000_B19","unstructured":"US Food and Drug Administration. Pediatric clinical studies of Sensipar (cinacalcet hydrochloride) suspended after report of death. 2-26-2013. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm340551.htm. Accessed 19 September 2017."},{"issue":"4","key":"2019041118054632000_B20","first-page":"1598","article-title":"Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism","volume":"81","author":"Kifor","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041118054632000_B21","unstructured":"Amgen Inc. Sensipar. Full prescribing information. Available at: http:\/\/pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/sensipar\/sensipar_pi_hcp_english.ashx. Updated May 2017. Accessed 19 September 2017."},{"issue":"1","key":"2019041118054632000_B22","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity","volume":"96","author":"Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041118054632000_B23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-14-0355","article-title":"The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice","volume":"171","author":"Schwarz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2019041118054632000_B24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/EP10311.RA","article-title":"Cost-effectiveness of parathyroidectomy for primary hyperparathyroidism","volume":"17","author":"Zanocco","year":"2011","journal-title":"Endocr Pract"},{"issue":"2","key":"2019041118054632000_B25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2796.2006.01684.x","article-title":"Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor","volume":"260","author":"Timmers","year":"2006","journal-title":"J Intern Med"},{"key":"2019041118054632000_B26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/1752-1947-5-564","article-title":"Clinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: a case series","volume":"5","author":"Rasmussen","year":"2011","journal-title":"J Med Case Reports"},{"issue":"14","key":"2019041118054632000_B27","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMc1511646","article-title":"Cinacalcet for symptomatic hypercalcemia caused by AP2S1 mutations","volume":"374","author":"Howles","year":"2016","journal-title":"N Engl J Med"},{"key":"2019041118054632000_B28","first-page":"140050","article-title":"Recurrent pancreatitis in a patient with familial hypocalciuric hypercalcaemia treated successfully with cinacalcet","volume":"2014","author":"Gunganah","year":"2014","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2019041118054632000_B29","first-page":"EP295","article-title":"Pancreatitis in familial hypocalciuric hypercalcaemia","volume":"37","author":"Potorac","year":"2015","journal-title":"Endocrine Abstracts"},{"key":"2019041118054632000_B30","first-page":"150040","article-title":"Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients","volume":"2015","author":"Fisher","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"10","key":"2019041118054632000_B31","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/102\/11\/3933\/21533644\/jc.2017-01606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T06:20:05Z","timestamp":1555050005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/102\/11\/3933\/4159879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,9,18]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2017-01606","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11,1]]},"published":{"date-parts":[[2017,9,18]]}}}